GSK plc has seen a significant rise in their stock due to key FDA approvals such as Nucala for COPD and Blenrep for cancer treatment. The company has also received accreditations for Depemokimab, thus indicating a shift towards respiratory and oncology growth. With multiple share buybacks and insider buying, the trust in the company has seen a boost in recent times. The shares of GSK have been rated highly by analysts due to the company's strong financials and the potential for long-term momentum. The company seems to be focusing on boosting the respiratory and immunology pipeline which is evident from the recent $2.2B RAPT buyout. Their shares rallied after the FDA approved Lynvoy, a drug for rare liver disease, and have acquired rights for a similar drug from Alfasigma, indicating potential in this specialty medicines space. The company has also recently outperformed in the market due to improved 2025 outlook thanks to lifts in cancer and HIV drug sales.
GSK Stocks News Analytics from Tue, 23 Sep 2025 07:00:00 GMT to Sat, 18 Apr 2026 18:32:55 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor 0
